About Us

Gifford Bioscience is a preclinical contract research organization (CRO) providing services in radioligand binding assays, receptor affinity and occupancy studies and autoradiography.

We are committed to delivering the best science. With this aim, we stick tightly to our core specialism and all of our researchers hold PhD’s.

We undertake standard or custom assays on our client’s samples to our client’s specification. In addition, our capabilities include assay design, cell culture, in-house production of membrane preparations and assays requiring human or animal tissue. 

We are based at The BioHub Birmingham.

CONTACT US for a chat. We are always happy to discuss potential requirements and assay design.

“Excellent work, high quality, very thorough and diligent. Love working with Gifford.”

Director Biology, Californian Biotech, Aug 2022

An international customer base:

Almost half of our clients are in the USA. A further quarter are based in the EU.


“We particularly appreciate the way your experienced scientists engage in scientific discourse with us, ensuring the optimal use of radioligand binding assays. Grateful for the excellent overall service.”

Associate Professor, East Coast University School of Medicine, Aug 2022

86% of our business is repeat business, coming from the scientists we have worked with before.


“We are so impressed with your serious scientific discussion, professional advice, and excellent service. We would like to commission many experiments with our other pipeline in the future, and I promise to introduce Gifford to many other groups. Thanks to all of you!”

Principal Researcher, Korean Biotech, 2021

“I am really impressed how fast and professionally you act. 😊. It is clear to me that you at Gifford like ‘doing science’ and challenges.”

Principal Scientist, German Pharma, 2021

“Our group discussed your initial KOR binding data in our meeting today. All were very impressed with the quality of your data.”

Board Member, Boston Biotech, 2021

The Management Team

Dr Andrew Gifford 

Chairman and Chief Scientific Officer

Andrew was previously a Senior Scientist in the radiopharmaceutical development program at Brookhaven National Laboratory, New York. As a Principal Investigator, he has been responsible for the preclinical development of a variety of radiolabeled drugs. Techniques employed in his academic laboratories were primarily radiometric ligand binding and occupancy assays, radiolabeling chemistry and autoradiography.

Andrew is a graduate of Imperial College, London and was awarded his PhD in Pharmacology by the University of St. Andrews.

He is an author of 52 peer-reviewed publications.

Mr Macer Gifford

Managing Director

Macer is a banker by profession. His 25 year career has spanned numerous senior roles. Most recently, he was Deputy Group CEO at Ahli United Bank. Macer was previously Group Head of Regional Markets at Standard Chartered PLC, where he spent 7 years as a Managing Director.

Macer is a graduate of the London School of Economics and a Sloan Fellow of the London Business School.

Dr Kevin Thompson

Operations Manager

Kevin has 25-years Pharma, Biotech and CRO experience. He joined Gifford Bioscience in 2019 from a position as director of Screening and Operations at a UK Biotech. Kevin has considerable in vitro screening experience applied to diverse therapeutic targets. He applies his in-depth knowledge of binding kinetics to also oversee the SPR (Biacore) assay services. Kevin is a Biology graduate and was awarded his DPhil in Neurobiology, both at Sussex University.

Copyright © 2008 – 2020 Gifford Bioscience Limited
Privacy Policy